Please assess the completion status of the following clinical trial:

Trial Title: Cell Therapy in Chagas Cardiomyopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of dilated cardiomyopathy according to WHO criteria~* Syndromic heart failure in functional class III or IV of the NYHA~* Enrollment and continuous follow-up in cardiac out-patient clinic~* Adequate medical therapy after optimization therapy~* Echocardiogram with an ejection fraction equal to or less than 35% by Simpson's rule~Exclusion Criteria:~* Valvular diseases, except functional mitral or tricuspid reflow~* Coronariography showing a significant lesion (obstruction of at least 50% of the lumen in the troncus or the main arteries - LAD, CX, RC) in one or more arteries~* Serologic diagnosis for Chagas disease or at least two of the following criteria: epidemiology, right bundle branch block, anterior hemi-block, apical aneurism~* Sustained ventricular tachycardia~* Abusive use of alcohol or illicit drugs~* Pregnancy~* Use of cardio toxic drugs~* Any co-morbidity with impact in life expectancy in 2 years~* Renal function compromised (creatinine above 2 mg/dl)~* Definitive implant of pace-makers, resynchronizers and CDIs~* Heart failure with symptoms initiating less than 1 year ago~* Active systemic arterial hypertension or history of hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Stem Cell therapy (Type: EXPERIMENTAL): Stem Cell therapy
- Standart therapy (Type: ACTIVE_COMPARATOR): Standart therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).